Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA)
Status:
Unknown status
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
This was a randomized, multi-center, partially placebo-controlled Phase IV study to compare
the efficacy and tolerability of a 48-week combined therapy with pegylated interferon
alpha-2a, ribavirin and amantadine sulphate versus placebo in untreated patients with chronic
hepatitis C virus-genotype-1-infection. The hypothesis was that there will be an increase in
sustained response rate for triple therapy compared to current standard treatment.